Free Trial

Butterfly Network (BFLY) Competitors

Butterfly Network logo
$2.35 -0.21 (-8.20%)
(As of 11/15/2024 ET)

BFLY vs. CNMD, WRBY, TNDM, NVCR, RXST, INMD, ESTA, BLFS, AORT, and PLSE

Should you be buying Butterfly Network stock or one of its competitors? The main competitors of Butterfly Network include CONMED (CNMD), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), NovoCure (NVCR), RxSight (RXST), InMode (INMD), Establishment Labs (ESTA), BioLife Solutions (BLFS), Artivion (AORT), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry.

Butterfly Network vs.

Butterfly Network (NYSE:BFLY) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Butterfly Network had 1 more articles in the media than CONMED. MarketBeat recorded 4 mentions for Butterfly Network and 3 mentions for CONMED. CONMED's average media sentiment score of 1.37 beat Butterfly Network's score of 0.67 indicating that CONMED is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Butterfly Network
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CONMED
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

37.8% of Butterfly Network shares are owned by institutional investors. 27.3% of Butterfly Network shares are owned by company insiders. Comparatively, 6.8% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CONMED has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Butterfly Network$76.22M6.57-$133.70M-$0.46-5.11
CONMED$1.24B1.79$64.46M$4.2117.16

Butterfly Network has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.

Butterfly Network presently has a consensus price target of $3.00, indicating a potential upside of 27.66%. CONMED has a consensus price target of $79.80, indicating a potential upside of 10.47%. Given Butterfly Network's stronger consensus rating and higher probable upside, equities analysts clearly believe Butterfly Network is more favorable than CONMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Butterfly Network
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
CONMED
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

CONMED received 28 more outperform votes than Butterfly Network when rated by MarketBeat users. However, 66.67% of users gave Butterfly Network an outperform vote while only 47.22% of users gave CONMED an outperform vote.

CompanyUnderperformOutperform
Butterfly NetworkOutperform Votes
6
66.67%
Underperform Votes
3
33.33%
CONMEDOutperform Votes
34
47.22%
Underperform Votes
38
52.78%

CONMED has a net margin of 10.23% compared to Butterfly Network's net margin of -129.25%. CONMED's return on equity of 13.84% beat Butterfly Network's return on equity.

Company Net Margins Return on Equity Return on Assets
Butterfly Network-129.25% -42.68% -30.31%
CONMED 10.23%13.84%5.26%

Summary

CONMED beats Butterfly Network on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFLY vs. The Competition

MetricButterfly NetworkX IndustryMedical SectorNYSE Exchange
Market Cap$500.70M$13.46B$5.06B$19.82B
Dividend YieldN/A1.83%5.09%3.50%
P/E Ratio-5.1123.03101.8542.31
Price / Sales6.579.551,196.8120.82
Price / CashN/A13.1140.9121.65
Price / Book2.762.416.334.66
Net Income-$133.70M$273.70M$119.64M$983.45M
7 Day Performance-10.31%-7.48%-5.12%-2.12%
1 Month Performance36.63%-7.88%-3.21%-0.47%
1 Year Performance111.71%11.72%32.52%24.69%

Butterfly Network Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BFLY
Butterfly Network
2.9116 of 5 stars
$2.35
-8.2%
$3.00
+27.7%
+111.7%$500.70M$65.90M-5.11460
CNMD
CONMED
4.8541 of 5 stars
$74.86
+1.9%
N/A-32.7%$2.31B$1.24B17.784,000Short Interest ↓
Positive News
WRBY
Warby Parker
2.3701 of 5 stars
$20.51
+5.1%
N/A+95.7%$2.06B$742.53M-75.963,491Gap Up
TNDM
Tandem Diabetes Care
4.5855 of 5 stars
$31.37
+2.5%
N/A+48.6%$2.06B$747.72M-16.252,400
NVCR
NovoCure
3.9285 of 5 stars
$18.19
+4.3%
N/A+36.2%$1.97B$509.34M-12.991,453Positive News
RXST
RxSight
3.0814 of 5 stars
$46.33
-3.5%
N/A+60.1%$1.71B$128.29M-55.82220Insider Buying
Short Interest ↑
News Coverage
INMD
InMode
3.4879 of 5 stars
$19.50
+0.5%
N/A-17.0%$1.64B$492.05M10.54480Short Interest ↓
ESTA
Establishment Labs
2.2196 of 5 stars
$45.29
-2.1%
N/A+63.1%$1.27B$165.15M-17.55960
BLFS
BioLife Solutions
2.4393 of 5 stars
$26.60
+1.8%
N/A+75.8%$1.23B$143.27M-15.74409Analyst Forecast
Analyst Revision
News Coverage
High Trading Volume
AORT
Artivion
1.9191 of 5 stars
$28.85
+0.5%
N/A+89.1%$1.21B$354M-1,442.501,500
PLSE
Pulse Biosciences
1.8326 of 5 stars
$18.78
-5.5%
N/A+166.7%$1.16B$700,000.000.00140Analyst Upgrade
Positive News

Related Companies and Tools


This page (NYSE:BFLY) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners